C4 Therapeutics Inc. (CCCC) carries a Roarable Rating of E (Strong Sell) with 27/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
C4 Therapeutics Inc. (CCCC) dropped -2.80% to $3.30, trading at 46% of its 52-week range ($1.69 – $5.17). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
C4 Therapeutics (CCCC) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
DEL Technology Integrating C4T’s Cereblon Library Can Rapidly Advance Projects Into Hit-To-Lead StageWATERTOWN, Mass., Oct. 29, 2026 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopha
Lake Street analyst Chad Messer initiates coverage on C4 Therapeutics (NASDAQ:CCCC) with a Buy rating and announces Price Target of $11.
For questions about this article or underlying research, email help@trefis.com.
Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced the a
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +1.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on CCCC today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for CCCC. Explore sector supply chains on /butterfly.
Across 1016 tracked Health Care securities in the Roarable RQD universe, C4 Therapeutics Inc. (CCCC) ranks #977 by composite RQD confidence (27/100, grade E) and #478 by equity capitalization ($406.0M). Within this direct 5-issuer industry benchmark cohort, CCCC leads on earnings valuation at N/A trailing P/E, while FENC leads on capital efficiency and profitability with -25.9% ROIC and — gross margin. AGMB currently holds the highest overall quantitative score in the immediate peer group at 51/100 (D) compared with CCCC at 27/100 (E).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| CCCC
ACTIVE
C4 Therapeutics Inc. | E | 27/100 | — | — | -35.0% | -2.80% | $406.0M | Benchmark Subject |
| TECX Tectonic Therapeutic Inc. | D- | 37/100 | — | — | -35.0% | -0.29% | $400.8M | /tecx-vs-cccc → |
| AUTL Autolus Therapeutics plc | E | 25/100 | — | -27.8% | -35.0% | -3.07% | $420.5M | /autl-vs-cccc → |
| AGMB AgomAb Therapeutics NV | D | 51/100 | — | — | — | -0.13% | $391.5M | /agmb-vs-cccc → |
| FENC Fennec Pharmaceuticals Inc. | D- | 36/100 | — | — | -25.9% | +0.74% | $383.6M | /fenc-vs-cccc → |
In its most recent audited fiscal period (FY2025, filed 2025-12-31), C4 Therapeutics Inc. (CCCC) reported GAAP revenue of $35.9M (+1.0% vs. FY2024 revenue of $35.6M , and +73.2% cumulative change since FY2023) , GAAP net income of -$105.0M, operating cash flow of -$98.7M, and free cash flow of -$99.3M (-52.0% YoY). On the balance sheet, CCCC closed FY2025 with $359.1M in total assets against $0 in total debt (Altman Z-Score: 0.20, Piotroski F-Score: 3/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $35.9M | -$105.0M | -$98.7M | -$99.3M | $359.1M | — |
| FY2024 (FY) | 2024-12-31 | $35.6M | -$105.3M | -$65.2M | -$65.3M | $349.6M | — |
| FY2023 (FY) | 2023-12-31 | $20.8M | -$132.5M | -$106.8M | -$106.8M | — | — |
As of 2026-11-01, C4 Therapeutics Inc. (NASDAQ: CCCC) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 27/100 at a spot price of $3.30 (-2.80% 1D, market cap $406.0M). Pillar breakdown: Fundamental Cash Engine 3/20, Institutional 13F & Options Flow 7/20, Executive Insider Alignment 5/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, CCCC ranks #977 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), CCCC carries a Roarable E (27/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, TECX (Tectonic Therapeutic Inc.) holds a D- grade (37/100 RQD, P/E N/A, ROIC -35.0%, cap $400.8M) and AUTL (Autolus Therapeutics plc) posts a E grade (25/100 RQD, P/E N/A, ROIC -35.0%, cap $420.5M). Among the 5-stock peer group, CCCC leads on earnings multiple (N/A) while FENC leads on capital efficiency (-25.9% ROIC).
Per CCCC's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001662579), C4 Therapeutics Inc. generated $35.9M in revenue (+1.0% YoY), -$105.0M in net income, and -$99.3M in free cash flow against $359.1M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
CCCC last traded at $3.30 (-2.80% on volume of 2,715,045 shares), positioning the stock -0.60% below its 50-day simple moving average ($3.32) and +2.80% above its 200-day simple moving average ($3.21). Across its 52-week range of $1.69 to $5.17, CCCC sits at the 46.3% percentile with a 14-day RSI of 57.0 (BULLISH MOMENTUM) and an implied next-earnings move of ±12.5% ($2.89 to $3.71).
Why CCCC Stock dropped -2.80% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.